Myriad Genetics Q4 Earnings Call Highlights

Raha highlighted volume growth in several areas, including MyRisk in oncology, with affected volumes up 14% and unaffected volumes up 11% year-over-year. He also pointed to an acceleration in Prolaris test volume growth to 12% year-over-year in the quarter, which he attributed to actions taken over the past two quarters, including incremental commercial investments focused on urologists.Wheeler said overall test volumes increased 2% year-over-year, while average revenue per test declined 2% year-over-year. ...